Sweden-based Orphan Biovitrum AB (publ) yesterday announced its financial results for the first quarter of 2019.

The company reported total revenues of SEK3,265m in the first quarter of 2019, up 66% over the year-ago period.

The firm posted earnings per share of SEK3.14 and adjusted EPS2 of SEK3.03 in the first quarter of 2019.

EBITA1 increased by 96% to SEK1,509m (771) and adjusted EBITA2 was SEK1,471m, an increase of 91%.

Guido Oelkers, Orphan Biovitrum CEO and president, said, 'We started 2019 with a strong first quarter, with revenues of SEK3,265m and EBITA of SEK1,509m, corresponding to an EBITA margin of 46%. We completed the acquisition of Synagis in late January and are in the process of integrating Synagis operations and employees into the organisation. The Haemophilia franchise continued to grow strongly, we have seen positive effects from the Gamifant launch in the US even though it is still in early launch phase, and we see an increasing demand for Synagis.'